oral mucosal injury associated with adjuvant targeted therapy postoperative NSCLC
Conditions
Interventions
control group:LongXueJieHanPian placebo
treatment group:LongXueJieHanPian
Sponsors
Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) NSCLC was confirmed by histological or cytopathology, and the TNM stage of lung cancer was stage IB-IIIA by AJCC 2) Postoperative adjuvant targeted therapy, oral mucositis grade (WHO standard) =1 at baseline; 3)Age =18 years old and =80 years old, both male and female; 4)ECOG score 0-2 points; 5) Estimated survival =3 months; 6) Volunteer to join the study, sign the informed consent, compliance is good, and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1) Unable to complete baseline assessment; 2) Patients with primary tumors of other sites; 3) Patients receiving hematopoietic stem cell transplantation; 4) Pregnant or lactating patients, mental patients; 5)Patients with severe, uncontrolled organic diseases or infections, such as decompensated heart, lung, and renal failure, which can not tolerate targeted therapy; 6) Patients with known allergy or intolerance to the investigational drug; 7)Other conditions that the investigators felt prevented patients from participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The disappearance rate of oral mucosal inflammation; | — |
Secondary
| Measure | Time frame |
|---|---|
| pain degree;Discontinuation rate of targeted therapy;Peripheral blood inflammatory index;Recurrence rate of oral mucosal inflammation;Duration of oral mucosal inflammation;clinical symptoms;Quality of life evaluation; | — |
Countries
China
Contacts
Public Contacthouwei
Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine
Outcome results
None listed